very our that Thank tremendous at everyone. across continues momentum, an market a and issued line updated of we top and our bottom After presentation have financial release afternoon, results LifeMD's all announcing corporate core on you, telehealth closed, key news third am posted report the ir.lifemd.com.
I quarter offerings. and pleased to good to results website telehealth business delivering strong our
of result $X.X adjusted the increasing was by This to our grew make versus revenue prior and to with telehealth XX% continued million. adjusted for quarter, telehealth of sequentially ahead $X.X by stand-alone EBITDA the to EBITDA guidance our quarter, For $XXX,XXX significant well gains XXX% million. telehealth profitability
of virtual health, our such key key treatment as including all management management our insomnia. as while LifeMD's strongly weight performed areas, smaller as growth with holistic platform program weight Importantly, in well and categories piece care men's our a of remains business,
rather areas. of LifeMD nearly it's business, is subscribers range platform not a comprehensive a patient stated care but clinical trusted by category-specific virtual a XXX,XXX I before, As across nationwide
As we through our on we manage our rapidly offerings. offerings key the our new differentiated of management capabilities; evolve changing differentiating further care offering business virtual focused expanding complementary health areas: very clinical to market; and one, X, offerings, to the X, X weight our and dynamics accelerating RexMD continue platform and of men's pharmacy remain growth
affiliated includes center, the I Regarding first very square National team which is we fulfillment volumes. features pleased area, announced This capable technology and foot we increasing our by report LifeMD's OTC our officially led a of automation pharmacy which state-of-the-art to rapidly Pennsylvania, in am professionals that XX,XXX tremendous yesterday. servicing prescription opened Pharmacy, facility and logistics of
We and patients. and delivery and offerings scale pharmacy a the pharmacy to mail expect Owning be individual in enables order also personalized to XXXX XX-state experience times. patient new the that product needs our and be to improve accretive of us operating efficiently introduce can
we of licensed licensure states, our As coming our XX expect to states and to the XX pharmacy today, in is all months. in expand
which growth the for programs build our and We're we've over at to to past pleased continue this affordability management payer contracting progress the quarter, patients. revenue pharmacy care these with in the is with scale. made cycle and we in of enabler private XXXX area especially and government services infrastructure optimize compliance and improves support and important Another programs, beyond our virtual with of the
states. commercial group medical service affiliated in across patients X to payers Our enrolled currently is multiple
least dominant rates insurance the to XX out beginning choosing one and states. rolling or contracted have we payers. be is program encouraging see we methodically, private strong By our of several with private While goal to been from payers reimbursement XXXX, use to across at acquisition patients costs end this health are for
weight one we More for currently underappreciated our Medicare the and treat an enormous to LifeMD remain care in launch on patients opportunity Medicare-eligible do and years come. and is think We of offerings, within track primary not the first half importantly, management in XXXX. we to this
Turning area. to the key second
last to quarter, one our tolerate discussed therapies enhancing GLP-X has options compounded quality access for management is may treatments. weight weight rapidly be of priorities the our branded who depth we GLP-X that offering. provides As of those non-GLP-X patients alternative and afford top to LifeMD or a not leading built able growing and program and management
working we Our patients commitment a trusted put patient's denies branded options third-party always by with compounding first. If pharmacies. has provide therapies, been insurance for GLP-X to coverage
will employers disappointed coverage lack XXXX, need payers, we're government we GLP-X manufacturers that and the will private in improve therapies, branded the GLP-X reduce Medicare, for current optimistic patients reach with including for of of GLP-X agreements While accessibility and medications. the from remain GLP-X use medications with branded compounded that and payers to
is and care their have therapy coverage If make branded insurance being we patients to to use effort to addition management, patients first, platform LifeMD coverage help a to LifeMD access therapy. come In first. GLP-X private weight patient every to insurance seeking related the branded
some the begin Medicare around in the will recent of XXXX uncertainty if do compounding will it that same coverage these understand for we anticipate GLP-X medications.
We thing there future for We expands, medications. to as is investors
provider is care is immediate uniquely it that LifeMD help any takes leading as and changes, and we what for metabolic virtual to first virtual anticipate raising not focused, access on do XX-state health-changing foremost, patients to medications. a care the believe we bar doing of While positioned, continue that
revenue takes collaborating look and Drug to services our That appropriate of will profits affordable vast comprehensive platform. the and said, U.S. do the forward what to majority follow We virtual to access and to and continue the care derived patients, lead medications. drive and it our payers LifeMD's that are of to partners with prescribing all Food from beyond medications across Administration go care
diet just lifestyle access journey, changes. essential to but make guidance not supporting committed also deeply offering sustainable step to their every are of personalized We patients through medications, and long-term health to
designed providing expert and effective are unique and patients to their resources, both receive long-term patients safe, we to their health. empower ensure needs, meaningful support to treatment. offerings during continuous sustainable tailored that to improvements their after make and care Our By
workflows During of the the management prior benefits implementation market key capabilities, made third non-GLP-X of estimate improve weight addressable treatment technology option additional the which rollout a optimized could AI-driven launch enhancements to in-home infrastructure. metformin, our authorization and and lab including model, several electronic and we of expand and quarter, LifeMD our topiramate, the by to XX% combining bupropion
to are that and next spending we still are will While U.S. essential in our early resilience health believe care the success they stages dominate of a these market decade. throughout long-term enhancements, we the in
RexMD scaled on offering Lastly, telehealth ED third U.S. earlier, almost the patients key offerings exceeding the had business, benefit of to make in recently, and remains its market. Xx. one through would until through spend management We the therapies we this during on annual health regarding dramatically the quarter respected weight progress We've which revenue, area with X,XXX third of that the and sexual begun the complementary Up the addressable expand of return launch net ad Rex a RexMD. other accelerating without $XX of new most men's brands capitalize in I day added under million our in X these with approach to to growth opportunities largest and mentioned telehealth generic over men's continue primarily
also development, protocol are comprehensive recently it's we compliance as long-term offering, retention and men's believe very early extensive to a qualify data, hormone is this on Following hormonal performance optimistic who other those, patients which Though launched for therapies. and both for our therapy us will receive as offering discussing well complementary we testosterone, replacement may offering. about appropriate very not first strong do too be begin prescription
incremental expect core personalized quarter compounded business. health double-digit offering the year. the in potential to has We we to addition, believe offer growth In RexMD's for therapies alone ED sexual next this of first drive
We hard the brand, which but under leverage a on and launching be health and marketed care the will also will technology concierge LifeMD are RexMD robust program, working men's platform. building
we and the will the offering health think the that and strong that brand. for exists demand trust across that access country from to Given there patients be care, difficulty know new RexMD high-quality existing this
on performance remains previously million now guided on range has in by of XXXX. peak It to quarter million the achieve in its of run end EBITDA $X rate to to WorkSimpli, month growth. run track basis per leveled returned out and for the the third As $X.X a rate the
from call Importantly, with of profitability revenue, of QX the business, as execution results. delivering which telehealth is over robust business year a to continues a XX% growing fire XX% LifeMD's summary all Marc? with to initiatives, core our I'll rapidly our revenue of turn Marc a portion represented just than that, our consolidated summary, the growth.
And telehealth coming financial to cylinders poised Benathen more and is total compared with of performance our continue and strategic provide ago.
In core to and on
